Evidence that the C-terminus of tissue factor pathway inhibitor (TFPI) is essential for its in vitro and in vivo interaction with lipoproteins.

No abstract is available for this paper.

• Publication year

  1993

• Venue

  Blood Coagulation and Fibrinolysis

• Publication date

  1993-10-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1097/00001721-199304050-00007PMID 8292720
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Inhibitory properties of full-length and truncated recombinant tissue factor pathway inhibitor (TFPI). Evidence that the third Kunitz-type domain of TFPI is not essential for the inhibition of factor VIIa-tissue factor complexes on cell surfaces.

  1993cited by this paper
• Pharmacokinetics of Full Length and Two-Domain Tissue Factor Pathway Inhibitor in Combination with Heparin in Rabbits

  1993cited by this paper
• Tissue factor pathway inhibitor: the carboxy-terminus is required for optimal inhibition of factor Xa.

  1992cited by this paper
• Clearance of Recombinant Tissue Factor Pathway Inhibitor (TFPI) in Rabbits

  1992cited by this paper
• Synergism between full length TFPI and heparin: evidence for TFPI as an important factor for the antithrombotic activity of heparin.

  1992cited by this paper
• Lipoprotein-associated coagulation inhibitor (LACI) is a cofactor for heparin: synergistic anticoagulant action between LACI and sulfated polysaccharides.

  1992cited by this paper
• Tissue factor pathway inhibitor with high anticoagulant activity is increased in post‐heparin plasma and in plasma from cancer patients

  1991cited by this paper
• Purification and properties of heparin-releasable lipoprotein-associated coagulation inhibitor.

  1991cited by this paper
• Inhibition of Extrinsic Pathway Inhibitor Shortens the Coagulation Time of Normal Plasma and of Hemophilia Plasma

  1991cited by this paper
• The C-terminus of tissue factor pathway inhibitor is essential to its anticoagulant activity.

  1991cited by this paper
• Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples.

  1991cited by this paper
• The anticoagulant effect in heparinized blood and plasma resulting from interactions with extrinsic pathway inhibitor.

  1991cited by this paper
• Simultaneous presence of tissue factor pathway inhibitor (TFPI) and low molecular weight heparin has a synergistic effect in different coagulation assays

  1991cited by this paper
• The coagulation cascade: initiation, maintenance, and regulation.

  1991cited by this paper
• The Extrinsic Pathway Inhibitor: A Regulator of Tissue Factor-Dependent Blood Coagulation

  1991cited by this paper
• Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor

  1989cited by this paper
• Purification and characterization of the lipoprotein-associated coagulation inhibitor from human plasma.

  1989cited by this paper
• Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitory domains.

  1988cited by this paper
• Heparin induces release of extrinsic coagulation pathway inhibitor (EPI).

  1988cited by this paper
• A sensitive assay of extrinsic coagulation pathway inhibitor (EPI) in plasma and plasma fractions.

  1987cited by this paper

• Major Reservoir for Heparin-Releasable TFPIα (Tissue Factor Pathway Inhibitor α) Is Extracellular Matrix

  2021cites this paper
• Role of exosite binding modulators in the inhibition of Fxa by TFPI

  2015cites this paper
• Syndecan-3 and TFPI Colocalize on the Surface of Endothelial-, Smooth Muscle-, and Cancer Cells

  2015cites this paper
• The role of the different Kunitz domains of TFPI in the down-regulation of the extrinsic coagulation pathway

  2015cites this paper
• Tissue Factor Pathway Inhibitor ( TFPI ) Factor Xa and Tissue Factor-Factor VIIa Small Peptides Blocking Inhibition of Enzymology :

  2014cites this paper
• Inhibitory effects of LDL-associated tissue factor pathway inhibitor.

  2014cites this paper
• Small Peptides Blocking Inhibition of Factor Xa and Tissue Factor-Factor VIIa by Tissue Factor Pathway Inhibitor (TFPI)*

  2013cites this paper
• Tissue factor pathway inhibitor: structure-function.

  2012cites this paper
• Tissue Factor Pathway Inhibitor: New Insights into an Old Inhibitor

  2012cites this paper
• Sepsis, coagulation and anticoagulants.

  2010cites this paper
• Endothelial-derived tissue factor pathway inhibitor regulates arterial thrombosis but is not required for development or hemostasis.

  2010cites this paper
• Tissue Factor Pathway

  2010cites this paper
• Further Insight Into the Heparin-Releasable and Glycosylphosphatidylinositol-Lipid— Anchored Forms of Tissue Factor Pathway Inhibitor

  2008cites this paper
• The haemostatic role of tissue factor pathway inhibitor.

  2007cites this paper
• Effect of a selective thromboxane A2 synthetase inhibitor on the systemic changes induced by circulating pancreatic phospholipase A2

  2006cites this paper
• Comparative Tissue Factor Pathway Inhibitor Release Potential of Heparins

  2005cites this paper
• Therapeutic intervention and targets for sepsis.

  2005cites this paper
• The vulnerable endothelium: priming the vascular endothelium for thrombosis with unfractionated heparin: biologic plausibility for observations from the Superior Yield of the New Strategy of Enoxaparin, Revascularization and GlYcoprotein IIb/IIIa Inhibitors (SYNERGY) trial.

  2005cites this paper
• Blood Coagulation and Atherothrombosis Hiroshi Ashikaga

  2004cites this paper
• Adrenomedullin augments the release and production of tissue factor pathway inhibitor in human aortic endothelial cells.

  2003cites this paper
• Quantification of heparin-induced TFPI release: a maximum release at low heparin dose.

  2002cites this paper
• Comparative Effects of Unfractionated Heparin and Low Molecular Weight Heparin on Vascular Endothelial Cell Tissue Factor Pathway Inhibitor Release: A Model for Assessing Intrinsic Thromboresistance

  2002cites this paper
• Tissue factor and coronary artery disease.

  2002cites this paper
• Structural mechanism for heparin-binding of the third Kunitz domain of human tissue factor pathway inhibitor.

  2002cites this paper
• Oxidized Low-density Lipoprotein Associates Strongly with Carboxy-terminal Domain of Tissue Factor Pathway Inhibitor and Reduces the Catalytic Activity of the Protein

  2002cites this paper
• Oxidation products of phospholipid-containing delta-9 fatty acids specifically impair the activity of tissue factor pathway inhibitor.

  2002cites this paper
• Tissue Factor Pathway Inhibitor (TFPI): Biochemistry, Genetics, and Implications for Thrombophilia. Tissue Factor Pathway Inhibitor (TFPI): Biochemie, Genetik und Stellenwert für die Thromboseneigung

  2001cites this paper
• Plasma Levels of Total and Free Tissue Factor Pathway Inhibitor (TFPI) as Individual Pharmacological Parameters of Various Heparins

  2001cites this paper
• Molecular Weight-Dependent Influence of Heparin on the Form of Tissue Factor Pathway Inhibitor Circulating in Plasma

  2001cites this paper
• Tissue factor pathway inhibitor activity in severe sepsis

  2001cites this paper
• Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia.

  2000cites this paper
• Physiological Function of Tissue Factor Pathway Inhibitor and Interaction with Heparins

  2000cites this paper
• Tissue Factor Pathway Inhibitor Binds to Platelet Thrombospondin-1*

  2000cites this paper
• fibrinolytic and cytokine response Tissue factor pathway inhibitor dose-dependently inhibits coagulation

  2000cites this paper
• Oxidized low-density lipoprotein impairs the anti-coagulant function of tissue-factor-pathway inhibitor through oxidative modification by its high association and accelerated degradation in cultured human endothelial cells.

  2000cites this paper
• Tissue factor pathway inhibitor for cardiovascular disorders

  2000cites this paper
• Heparin Induces Synthesis and Secretion of Tissue Factor Pathway Inhibitor from Endothelial Cells In Vitro

  2000cites this paper
• Tissue Factor and the Influence of Lipoprotein Oxidation Comparison of the Inhibitory Effects of ApoB 100 and Tissue Factor Pathway Inhibitor on

  1999cites this paper
• Cellular effects of heparin on the production and release of tissue factor pathway inhibitor in human endothelial cells in culture.

  1999cites this paper
• Comparison of the inhibitory effects of ApoB100 and tissue factor pathway inhibitor on tissue factor and the influence of lipoprotein oxidation.

  1999cites this paper
• Inhibition of Tissue Factor-Factor VIIa-catalyzed Factor X Activation by Factor Xa-Tissue Factor Pathway Inhibitor

  1999cites this paper
• TFPIβ, a Second Product from the Mouse Tissue Factor Pathway Inhibitor (TFPI) Gene

  1999cites this paper
• New Potential Therapeutic Modalities: Tissue Factor Pathway Inhibitor

  1999cites this paper
• Changes in plasma tissue factor pathway inhibitor levels during the clinical course of disseminated intravascular coagulation

  1998cites this paper
• Factor Xa Cleavage of Tissue Factor Pathway Inhibitor Is Associated with Loss of Anticoagulant Activity

  1998cites this paper
• Recombinant TFPI and variants: potential implications in the treatment of cardiovascular disorders.

  1998cites this paper
• The Importance of the Binding of Factor Xa to Phospholipids in the Inhibitory Mechanism of Tissue Factor Pathway Inhibitor: The Transmembrane and Cytoplasmic Domains of Tissue Factor Are not Essential for the Inhibitory Action of Tissue Factor Pathway Inhibitor

  1997cites this paper
• Detection of the Three Kunitz-Type Single Domains of Membrane-Bound Tissue Factor Pathway Inhibitor (TFPI) by Flow Cytometry

  1997cites this paper
• Increased tissue factor pathway inhibitor in patients with acute myocardial infarction

  1997cites this paper
• Tissue factor pathway inhibitor in complex with low density lipoprotein isolated from human plasma does not possess anticoagulant function in tissue factor-induced coagulation in vitro.

  1997cites this paper
• An enzyme linked immunosorption assay for tissue factor pathway inhibitor.

  1997cites this paper
• Tissue factor pathway inhibitor: from unknown coagulation inhibitor to major antithrombotic principle.

  1997cites this paper
• Factor Xa Enhances the Binding of Tissue Factor Pathway Inhibitor to Acidic Phospholipids

  1996cites this paper
• Depletion of Intravascular Pools of Tissue Factor Pathway Inhibitor (TFPI) during Repeated or Continuous Intravenous Infusion of Heparin in Man

  1996cites this paper
• Tissue factor pathway inhibitor: regulation of its inhibitory activity by phospholipid surfaces.

  1996cites this paper
• Regulation of the extrinsic pathway system in health and disease: the role of factor VIIa and tissue factor pathway inhibitor.

  1995cites this paper
• Tissue Factor Pathway Inhibitor Activity in Patients With IDDM

  1995cites this paper
• Tissue Factor Pathway Inhibitor

  1995cites this paper
• Tissue factor pathway inhibitor activity in human plasma. Measurement of lipoprotein-associated and free forms in hyperlipidemia.

  1995cites this paper
• An anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody recognized the third Kunitz domain (K3) of free-form TFPI but not lipoprotein-associated forms in plasma.

  1995cites this paper
• Characterization of the binding between tissue factor pathway inhibitor and glycosaminoglycans.

  1994cites this paper
• Recent Progress on Tissue Factor Pathway Inhibitor (TFPI)

  1994cites this paper
• Inhibitory effects of TFPI variants on thrombin and factor Xa generation in fibrinogen-deficient human plasma.

  1994cites this paper
• Oxidized low-density lipoprotein impairs the anticoagulant function of tissue-factor-pathway inhibitor through oxidative modification by its high association and accelerated degradation in cultured human endothelial cells

  year unknowncites this paper